Advent announces manufacture of COVID-19 vaccine for phase 2/3 trials


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ advent-announces-manufacture-coronavirus-vaccine-oxford-university-trials
IRBM’S ADVENT manufactures 13000 doses of the vaccine to be used in clinical trials by Oxford University

Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222).

The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford, England.

Following a long history of partnership, including the announcement on 7 February of an agreement between The Jenner Institute and IRBM’s Advent to manufacture ChAdOx1 nCoV-19, Advent has now manufactured its first batch of vaccine in just over one month from receiving the seed stock, whilst ensuring high standards of quality control. Over the past decade, Advent has manufactured hundreds of thousands of doses of vaccine for over 10 different infectious diseases. The company has achieved a 100% success rate for the approval of clinical grade quality batches by regulatory authorities.

Advent rapidly devised a manufacturing process incorporating high quality process development, and extensive quality control, to produce 13,000 doses of the vaccine for use in Phase 2/3 clinical trials. With Phase I trials already enrolled for this vaccine, rapid and reliable development of a large scale manufacturing process is a critical step in quickly and safely delivering the vaccine for further trials.

Professor Sarah Gilbert of the Jenner Institute said: “Speed is of the essence when facing a new outbreak such as this unprecedented Covid-19 pandemic. Advent has manufactured and delivered the vaccine very quickly, producing a clinical batch in just over one month since we provided the seed stock, enabling us to rapidly prepare for larger scale clinical trials.”

Dr Piero Di Lorenzo, President and CEO of ADVENT and IRBM said: “Our scientists have been working tirelessly, and with great passion, to manufacture and support the development of the COVID-19 vaccine for clinical trials. Rapid and reliable manufacturing of high quality batches of the vaccine for clinical trials will be a critical step in getting it approved for use in people in order to overcome this global pandemic.”

The vaccine comprises a non-replicating adenovirus vector with the addition of the SARS-CoV-2 spike protein of the COVID-19 virus. It is hoped that the vaccine will result in people forming antibodies to the COVID-19 spike proteins, which should prevent infection and generate immunity in the tested population. On 30th April, the University of Oxford announced a landmark partnership with AstraZeneca for the development and potential large-scale distribution of COVID-19 vaccine candidate.

Advent is a world-class contract manufacturing organization and part of the IRBM group located outside Rome, within the IRBM campus. The facility complies with the regulatory guidelines of both FDA and EMA and has been granted the authorization to produce investigational medicinal products by the Italian National Regulatory Authority (AIFA).

Advent is currently focused on the development and manufacture of investigational lots of adenovirus-based vaccines.

Tags : #AdventSrI #COVID-19Vaccine #ProfSarahGilbert #DrPieroDiLorenzo

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026